Evidence mapPaperPMID 40427786Full record

SynthesisInternational journal of environmental research and public health2025

COVID-19 Disease and Economic Burden to Healthcare Systems in Adults in Six Latin American Countries Before Nationwide Vaccination Program: Ministry of Health Database Assessment and Literature Review.

Natalia Espinola, Cecilia I Loudet, Rosario Luxardo, Carolina Moreno, Moe H Kyaw, Julia Spinardi, Carlos Fernando Mendoza, Carolina M Carballo, Ana Carolina Dantas, Maria Gabriela Abalos and 3 more

Abstract readSystematic Review
In one paragraph

Synthesis in International journal of environmental research and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Natalia EspinolaDepartment of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires City C1414, Argentina.ORCID 0000-0001-5511-3561
Cecilia I LoudetDepartment of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires City C1414, Argentina.ORCID 0000-0002-1647-5110
Rosario LuxardoDepartment of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires City C1414, Argentina.
Carolina MorenoDepartment of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires City C1414, Argentina.
Moe H KyawVaccine, Medical, Pfizer Inc., New York, NY 10001, USA.ORCID 0000-0002-0258-6645
Julia SpinardiVaccine, Medical, Emerging Markets, Pfizer Inc., Itapevi 06696-000, Brazil.ORCID 0000-0002-4324-0317
Carlos Fernando MendozaVaccine HTA, Value and Evidence, Pfizer Inc., Mexico City 05120, Mexico.ORCID 0000-0002-2685-9548
Carolina M CarballoVaccines, Medical, Pfizer Inc., Buenos Aires City C1437, Argentina.
Ana Carolina DantasVaccines, Medical, Pfizer Inc., Buenos Aires City C1437, Argentina.
Maria Gabriela AbalosVaccine HTA, Value and Evidence, Pfizer Inc., Mexico City 05120, Mexico.
Jamile BallivianDepartment of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires City C1414, Argentina.ORCID 0000-0002-2495-8040
Emiliano NavarroDepartment of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires City C1414, Argentina.
Ariel BardachDepartment of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires City C1414, Argentina.ORCID 0000-0003-4437-0073

Funding

Pfizer NA
6 · The paper itself

Abstract

The COVID-19 pandemic imposed a substantial burden on healthcare systems worldwide, yet reliable data on COVID-19 morbidity, mortality, and healthcare costs in Latin America remain limited. This study explored the disease and economic burden of COVID-19 in Argentina, Brazil, Chile, Colombia, Mexico, and Peru during the pre-vaccination period. Using national databases and a systematic review of the literature, we analyzed data on adults aged 18 and older, reporting cases, death rates, years of life lost, excess mortality, and direct medical costs. Before vaccination programs began, the average COVID-19 incidence rate was 6741 per 100,000 adults. Of these, 91% were mild cases, 7% moderate/severe, and 2% critical. Among 2,201,816 hospitalizations, 27.8% required intensive care, and 17.5% required mechanical ventilation. Excess mortality ranged from 76 to 557 per 100,000, and years of life lost spanned 241,089 to 3,312,346. Direct medical costs ranged from USD 258 million to USD 10,437 million, representing 2-5% of national health expenditures. The findings highlight significant variability across countries and provide crucial insights to help policymakers to make informed decisions and allocate resources effectively to improve national strategies around surveillance, preventive and treatment strategies to control the spread of COVID-19 disease in the future.

Indexed as

Cost of IllnessCOVID-19Health Care CostsAdultAgedDatabases, FactualHospitalizationHumansLatin AmericaMiddle AgedSARS-CoV-2Young AdultadultsCOVID-19disease burdeneconomic burdenLatin American

Identifiers

PMID40427786
PMCPMC12111093

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.